Key result
4-factor prothrombin complex concentrate use in major bleeding is linked to ~1.5% thromboembolic risk.
Why the study?
Limited real-world data were available globally and within Japan regarding the safety and effectiveness of 4-factor prothrombin complex concentrate in patients experiencing major hemorrhage or requiring expeditious surgical intervention.
Observational (n=1,381)
Yes
In a real-world Japanese cohort, 4-factor prothrombin complex concentrate effectively reversed anticoagulation in patients with major bleeding or requiring urgent surgery, with a low 1.5% incidence of thromboembolic events.
May support 4-factor PCC reversal in Japanese patients; leaves open generalizability and causality without randomized trials.
INTRODUCTION: Limited data are available regarding the safety and effectiveness of 4-factor prothrombin complex concentrate (4F-PCC) in patients experiencing major hemorrhage or requiring expeditious surgical intervention, both globally and within Japan. METHODS: We executed a prospective, observational post-marketing surveillance study of patients receiving 4F-PCC for the first time between September 19, 2017 and August 15, 2018 in Japan. Patients were subjected to a comprehensive follow-up for a duration of 4 weeks. RESULTS: Of 1381 eligible patients, 1271 (92%) received a vitamin K antagonist. Among these, 58% were aged ≥ 75 years, 49% manifested atrial fibrillation, 17% presented with valvular heart disease, and 6% exhibited venous thromboembolism. The median (range) international normalized ratio was 2.67 (0.96-27.11) at baseline and 1.21 (0.45-6.61) at first measurement post-administration of 4F-PCC. The most common reason for 4F-PCC administration was intracranial hemorrhage (59.6%), followed by gastrointestinal bleeding (6.6%). Hemostatic effectiveness was achieved in 85.8% of patients. The incidences of adverse drug reactions (ADRs) and serious ADRs were 3.9% and 2.8%, respectively. Thromboembolic events (TEEs) occurred in 20 (1.5%) patients, with a mean onset of 10 days. The majority of TEEs were classified as nervous system disorders (55%). At the time of TEE, only 13% of patients resumed anticoagulant therapy. CONCLUSION: The incidence of TEEs following treatment with 4F-PCC did not surpass those observed in phase 3 trials. No novel safety signals were identified. The safety and effectiveness of 4F-PCC in Japanese real-world practice were in harmony with the observations of prior studies.
No takes yet. Share an insight, caveat, or question.
Yasaka et al. (2024) conducted an observational in Major bleeding or requiring urgent surgical intervention (n=1,381). 4-factor prothrombin complex concentrate (4F-PCC) was evaluated on Incidence of thromboembolic events (TEEs). In Japanese patients experiencing major bleeding or requiring urgent surgery, 4-factor prothrombin complex concentrate was effective and associated with a 1.5% incidence of thromboembolic events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: